Ali Buwaider, Mathan Kananathan, Sara Tabari, Sofia Hylin, Bodo Lippitz, Elfar Úlfarsson, Petter Förander, Michael Gubanski, Tiit Mathiesen, Alexander Fletcher-Sandersjöö, Jiri Bartek
{"title":"伽玛刀放射治疗颅咽管瘤后的长期结果:瑞典全国队列平均随访21年。","authors":"Ali Buwaider, Mathan Kananathan, Sara Tabari, Sofia Hylin, Bodo Lippitz, Elfar Úlfarsson, Petter Förander, Michael Gubanski, Tiit Mathiesen, Alexander Fletcher-Sandersjöö, Jiri Bartek","doi":"10.1227/neu.0000000000003394","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Craniopharyngiomas are rare intracranial tumors associated with a high recurrence rate. Gamma Knife radiosurgery (GKRS) is a widely used modality to treat these tumors, either as primary or secondary treatment. Long-term control is desired, yet available evidence on the long-term efficacy of GKRS remains unknown because of the limited follow-up periods in existing studies. The aim of this study was to assess long-term outcomes of GKRS-treated craniopharyngiomas in a nationwide consecutive cohort.</p><p><strong>Methods: </strong>All patients with craniopharyngiomas who were treated by GKRS at the Karolinska University Hospital between 1968 and 2010 were included. Progression-free survival (PFS), overall survival (OS), and potential predictors of tumor growth and survival were assessed.</p><p><strong>Results: </strong>A total of 44 patients were included. Follow-up times ranged from 4 to 55 years, with a mean of 21 years and a median of 19 years. PFS was 64% at 5 years, 50% at 10 years, 45% at 20 years, and 40% at 30 years. No growth occurred after 30 years in patients who had been progression free until that point. 69% of recurrences required further treatment. OS was 91% at 5 years, 79% at 10 years, 64% at 20 years, and 64% at 30 years. Tumor volume was an independent predictor of tumor growth (OR 1.69, P = .020), and age (OR 1.07, P = .018) and tumor volume (OR 1.21, P = .049) were independent predictors of survival.</p><p><strong>Conclusion: </strong>GKRS demonstrates sustained long-term efficacy in treating craniopharyngiomas, with a PFS rate of 40% at 30 years and no tumor growth observed beyond this point. Initial tumor volume should be assessed when planning GKRS treatment and follow-up of craniopharyngioma patients because it is a significant predictor of both tumor growth and OS.</p>","PeriodicalId":19276,"journal":{"name":"Neurosurgery","volume":" ","pages":"657-670"},"PeriodicalIF":3.9000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-Term Outcomes After Gamma Knife Radiosurgery Treatment of Craniopharyngiomas: A Swedish Nationwide Cohort With a Mean Follow-Up of 21 Years.\",\"authors\":\"Ali Buwaider, Mathan Kananathan, Sara Tabari, Sofia Hylin, Bodo Lippitz, Elfar Úlfarsson, Petter Förander, Michael Gubanski, Tiit Mathiesen, Alexander Fletcher-Sandersjöö, Jiri Bartek\",\"doi\":\"10.1227/neu.0000000000003394\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Craniopharyngiomas are rare intracranial tumors associated with a high recurrence rate. Gamma Knife radiosurgery (GKRS) is a widely used modality to treat these tumors, either as primary or secondary treatment. Long-term control is desired, yet available evidence on the long-term efficacy of GKRS remains unknown because of the limited follow-up periods in existing studies. The aim of this study was to assess long-term outcomes of GKRS-treated craniopharyngiomas in a nationwide consecutive cohort.</p><p><strong>Methods: </strong>All patients with craniopharyngiomas who were treated by GKRS at the Karolinska University Hospital between 1968 and 2010 were included. Progression-free survival (PFS), overall survival (OS), and potential predictors of tumor growth and survival were assessed.</p><p><strong>Results: </strong>A total of 44 patients were included. Follow-up times ranged from 4 to 55 years, with a mean of 21 years and a median of 19 years. PFS was 64% at 5 years, 50% at 10 years, 45% at 20 years, and 40% at 30 years. No growth occurred after 30 years in patients who had been progression free until that point. 69% of recurrences required further treatment. OS was 91% at 5 years, 79% at 10 years, 64% at 20 years, and 64% at 30 years. Tumor volume was an independent predictor of tumor growth (OR 1.69, P = .020), and age (OR 1.07, P = .018) and tumor volume (OR 1.21, P = .049) were independent predictors of survival.</p><p><strong>Conclusion: </strong>GKRS demonstrates sustained long-term efficacy in treating craniopharyngiomas, with a PFS rate of 40% at 30 years and no tumor growth observed beyond this point. Initial tumor volume should be assessed when planning GKRS treatment and follow-up of craniopharyngioma patients because it is a significant predictor of both tumor growth and OS.</p>\",\"PeriodicalId\":19276,\"journal\":{\"name\":\"Neurosurgery\",\"volume\":\" \",\"pages\":\"657-670\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurosurgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1227/neu.0000000000003394\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1227/neu.0000000000003394","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景与目的:颅咽管瘤是一种罕见的颅内肿瘤,复发率高。伽玛刀放射外科(GKRS)是一种广泛使用的治疗这些肿瘤的方式,无论是作为主要治疗还是次要治疗。需要长期控制,但由于现有研究的随访时间有限,关于GKRS长期疗效的现有证据仍然未知。本研究的目的是在全国连续队列中评估gkrs治疗颅咽管瘤的长期预后。方法:纳入1968年至2010年间在卡罗林斯卡大学医院接受GKRS治疗的所有颅咽管瘤患者。评估无进展生存期(PFS)、总生存期(OS)以及肿瘤生长和生存的潜在预测因素。结果:共纳入44例患者。随访时间4 ~ 55年,平均21年,中位19年。5年PFS为64%,10年为50%,20年为45%,30年为40%。30年后,在此之前没有进展的患者没有出现生长。69%的复发患者需要进一步治疗。5年生存率为91%,10年为79%,20年为64%,30年为64%。肿瘤体积是肿瘤生长的独立预测因子(OR 1.69, P = 0.020),年龄(OR 1.07, P = 0.018)和肿瘤体积(OR 1.21, P = 0.049)是生存的独立预测因子。结论:GKRS在治疗颅咽管瘤方面表现出持续的长期疗效,30年PFS率为40%,超过30年未观察到肿瘤生长。在计划GKRS治疗和颅咽管瘤患者随访时,应评估初始肿瘤体积,因为它是肿瘤生长和OS的重要预测因子。
Long-Term Outcomes After Gamma Knife Radiosurgery Treatment of Craniopharyngiomas: A Swedish Nationwide Cohort With a Mean Follow-Up of 21 Years.
Background and objectives: Craniopharyngiomas are rare intracranial tumors associated with a high recurrence rate. Gamma Knife radiosurgery (GKRS) is a widely used modality to treat these tumors, either as primary or secondary treatment. Long-term control is desired, yet available evidence on the long-term efficacy of GKRS remains unknown because of the limited follow-up periods in existing studies. The aim of this study was to assess long-term outcomes of GKRS-treated craniopharyngiomas in a nationwide consecutive cohort.
Methods: All patients with craniopharyngiomas who were treated by GKRS at the Karolinska University Hospital between 1968 and 2010 were included. Progression-free survival (PFS), overall survival (OS), and potential predictors of tumor growth and survival were assessed.
Results: A total of 44 patients were included. Follow-up times ranged from 4 to 55 years, with a mean of 21 years and a median of 19 years. PFS was 64% at 5 years, 50% at 10 years, 45% at 20 years, and 40% at 30 years. No growth occurred after 30 years in patients who had been progression free until that point. 69% of recurrences required further treatment. OS was 91% at 5 years, 79% at 10 years, 64% at 20 years, and 64% at 30 years. Tumor volume was an independent predictor of tumor growth (OR 1.69, P = .020), and age (OR 1.07, P = .018) and tumor volume (OR 1.21, P = .049) were independent predictors of survival.
Conclusion: GKRS demonstrates sustained long-term efficacy in treating craniopharyngiomas, with a PFS rate of 40% at 30 years and no tumor growth observed beyond this point. Initial tumor volume should be assessed when planning GKRS treatment and follow-up of craniopharyngioma patients because it is a significant predictor of both tumor growth and OS.
期刊介绍:
Neurosurgery, the official journal of the Congress of Neurological Surgeons, publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology, and medicine. For professionals aware of the rapid pace of developments in the field, this journal is nothing short of indispensable as the most complete window on the contemporary field of neurosurgery.
Neurosurgery is the fastest-growing journal in the field, with a worldwide reputation for reliable coverage delivered with a fresh and dynamic outlook.